FTC puts conditions on Hikma proposed acquisition of Roxane units

29 February 2016

Jordon-based drug manufacturer Hikma Pharmaceuticals (LSE: HIK) will sell the rights and assets for two generic drugs, and relinquish its US marketing rights to a third generic drug, in order to settle US Federal Trade Commission charges that Hikma’s proposed acquisition of Roxane from German family-owned pharma major Boehringer Ingelheim would likely be anticompetitive.

Earlier this month Hikma revised the terms for its buy of the Roxane Laboratories unit (The Pharma Letter February 10), reducing the amount it pays Boehringer to a gross consideration of $647 million in cash as opposed to $1.18 billion, a reduction of $535 million.

Accord requires divestment to Renaissance and Unimark

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK